Bayer's Spending Plans and Pipeline Progress Don't Yet Add Up to Earnings
Published on 10/24/2026 at 07:11 | Editorial boerse-global.de
Bayer has given investors plenty to weigh this autumn: a multibillion-dollar manufacturing commitment, a regulatory filing that has cleared its first hurdle, and a pair of analyst notes that pull in opposite directions on the near-term numbers. What none of it delivers is a read on actual profit.
At the center of the debate sits the split between revenue and earnings power. JPMorgan, in a note published roughly a week ago, kept an "Overweight" rating on the stock with a price target of 61 euros. Analyst Richard Vosser's sales forecast ran 2% above consensus, yet his estimate for earnings before interest, taxes, depreciation and amortization came in 6% below it. A bullish recommendation, in other words, without a uniformly bullish operating view. Vosser also expected Bayer to reaffirm its full-year guidance—his projection, not a company commitment.
A $2.2 Billion Bet on Ohio
On the industrial side, Bayer said on October 2 that it will invest $2.2 billion in a new pharmaceutical production site in New Albany, Ohio, with roughly 600 jobs expected to follow. The outlay builds manufacturing capacity; it does not, on its own, translate into revenue. That distinction matters when reading the announcement alongside the company's drug-development news.
The regulatory thread runs through Finerenon, marketed as Kerendia. About two weeks ago the US Food and Drug Administration accepted Bayer's supplemental application for the drug in adults with chronic kidney disease who do not have diabetes, a filing backed by positive results from the Phase III FIND-CKD trial. Acceptance is a procedural step, not an approval—the proposed additional use has not been cleared, and the filing cannot be equated with an already-opened market.
Should investors sell immediately? Or is it worth buying Bayer?
UBS Sticks With Its Call
UBS weighed in on October 15, reaffirming a "Buy" rating and a 62-euro price target. Matthew Weston pointed to sustained Crop Science trends for 2026 and 2027 as well as momentum in the pharmaceuticals division. His focus also took in the potential US approval of Asundexian—an approval that has not been granted and cannot be inferred from the note.
The same day, Bayer published an agricultural study that sketched a tougher backdrop for European farming. Production growth in the region is lagging behind key agricultural markets, the company said, with geopolitical strains and the effects of climate change adding further pressure on farmers. The study describes the environment Bayer's customers operate in; it says nothing specific about Bayer's own revenue or profit contribution, and challenges facing growers do not map directly onto the company's results.
What November 3 Will Settle
Bayer reports third-quarter 2026 results on November 3. Revenue will be only part of the story. Just as telling will be the strength of earnings power and whether management actually confirms the annual outlook—the gap between a favorable stock rating and hard evidence of operating strength.
Until then, investors are left holding three separate threads: an announced capacity build-out, regulatory progress on a single medicine, and the business performance yet to be reported. Each offers a concrete data point. None pre-empts the numbers.
Ad
Bayer Stock: New Analysis - 24 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
